Mandate

Vinge assists Nuevolution in connection with Amgen’s cash offer

Vinge has assisted Nuevolution AB (publ) (“Nuevolution”) in connection with the cash offer to the shareholders in Nuevolution by Amgen Inc. (“Amgen”).

Nuevolution is a molecule drug discovery biotech company, listed on Nasdaq Stockholm. 

Amgen is one of the world’s leading biotechnology companies, with a vision deeply rooted in innovative science. Amgen’s shares are listed on Nasdaq in the United States.

Amgen offers SEK 32.50 in cash for every share in Nuevolution. The offer value amounts to approximately SEK 1,610 million.
 
Vinge’s team has primarily consisted of David Andersson, Dain Hård Nevonen, Ludvig Frithiof and William Kåge.

Related

Vinge advises HAKI Safety AB in connection with the acquisition of Trimtec

Trimtec is a Swedish distributor of high-tech precision equipment.
February 14, 2025

Vinge advises Industrifonden in connection with its investment in Agteria Biotech

Vinge has advised Industrifonden in connection with their participation as lead investor, together with AgriZeroNZ, in the seed financing round in Agteria Biotech AB.
February 13, 2025

Vinge advises Axcel and Accru Partners in connection with the acquisition of Sporrong & Eriksson Revisionsbyrå AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisition of Sporrong & Eriksson Revisionsbyrå AB.
February 12, 2025